CDER/CBER proprietary names meeting
Executive Summary
CDER and CBER will hold a public meeting June 5 to prepare for a pilot program on enabling pharmaceutical firms to evaluate proposed proprietary names and submit data generated from those evaluations to FDA for review (1"The Pink Sheet," Jan. 14, 2008, p. 15). The agenda includes a concept paper describing the logistics of the pilot program, proposed recommendations for carrying out a proprietary name review and the way FDA intends to review submissions. FDA plans to issue the concept paper by the end of this fiscal year and begin the pilot in FY 2009
You may also be interested in...
Brand Names In 2008: Can Industry Pilot Its Way Out Of Trouble?
Industry may shoulder some of the burden of testing proprietary drug names this year under a pilot program included in the renewal of the Prescription Drug User Fee Act, but with that may come some clarity in a subjective field that so far has lacked detailed guidance from FDA
California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits
The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.